Q1 2026 Holdings
Filed 2026-05-15 | 41 holdings | $1.3B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| DBV Technologies S A(DBVT) | SPONSORED ADS | 23306J309 | $108.9M | 5,213,361 | 8.4% |
| Cullinan Therapeutics, Inc.(CGEM) | Common | 230031106 | $108.7M | 7,648,268 | 8.4% |
| Aktis Oncology, Inc.(AKTS) | Common | 01021M104 | $86.5M | 4,835,872 | 6.7% |
| Liquidia Corporation(LQDA) | Common | 53635D202 | $53.0M | 1,405,158 | 4.1% |
| Alumis Inc(ALMS) | Common | 022307102 | $52.6M | 2,386,529 | 4.1% |
| Edgewise Therapeutics Inc(EWTX) | Common | 28036F105 | $52.3M | 1,660,696 | 4.0% |
| Revolution Medicines, Inc.(RVMD) | Common | 76155X100 | $49.3M | 506,776 | 3.8% |
| Agios Pharmaceuticals Inc(AGIO) | Common | 00847X104 | $44.2M | 1,306,261 | 3.4% |
| Corcept Therapeutics, Inc.(CORT) | Common | 218352102 | $39.7M | 985,700 | 3.1% |
| Trevi Therapeutics Inc(TRVI) | Common | 89532M101 | $39.4M | 3,298,430 | 3.0% |
| Dianthus Therapeutics Inc(DNTH) | Common | 252828108 | $35.6M | 423,982 | 2.7% |
| Xenon Pharmaceuticals Inc(XENE) | Common | 98420N105 | $34.2M | 588,706 | 2.6% |
| MoonLake Immunotherapeutics(MLTX) | Class A Ord | 61559X104 | $33.8M | 1,811,082 | 2.6% |
| Travere Therapeutics Inc(TVTX) | Common | 89422G107 | $33.7M | 1,133,365 | 2.6% |
| Evommune Inc(EVMN) | Common | 30054Y107 | $33.5M | 1,455,863 | 2.6% |
| Cytokinetics Inc(CYTK) | Common | 23282W605 | $33.0M | 500,000 | 2.5% |
| Syndax Pharmaceuticals Inc(SNDX) | Common | 87164F105 | $31.3M | 1,340,733 | 2.4% |
| Context Therapeutics Inc(CNTX) | Common | 21077P108 | $28.0M | 10,679,391 | 2.2% |
| Forte Biosciences, Inc.(FBRX) | Common | 34962G208 | $25.9M | 1,000,682 | 2.0% |
| Palvella Therapeutics Inc(PVLA) | Common | 697947109 | $25.7M | 206,404 | 2.0% |
| Dyne Therapeutics, Inc.(DYN) | Common | 26818M108 | $25.5M | 1,408,152 | 2.0% |
| Stoke Therapeutics Inc(STOK) | Common | 86150R107 | $25.0M | 767,038 | 1.9% |
| Corvus Pharmaceuticals Inc(CRVS) | Common | 221015100 | $24.5M | 1,674,875 | 1.9% |
| Relay Therapeutics Inc.(RLAY) | Common | 75943R102 | $23.5M | 2,359,586 | 1.8% |
| Tarsus Pharmaceuticals Inc(TARS) | Common | 87650L103 | $23.1M | 329,750 | 1.8% |
| Oric Pharmaceuticals Inc(ORIC) | Common | 68622P109 | $22.9M | 1,803,945 | 1.8% |
| Uniqure NV(QURE) | Common | N90064101 | $22.4M | 1,369,231 | 1.7% |
| Monte Rosa Therapeutics Inc(GLUE) | Common | 61225M102 | $19.4M | 1,176,928 | 1.5% |
| Natera Inc(NTRA) | Common | 632307104 | $18.6M | 93,074 | 1.4% |
| Climb Bio Inc(CLYM) | Common | 28658R106 | $17.8M | 2,593,439 | 1.4% |
| Arcutis Biotherapeutics Inc(ARQT) | Common | 03969K108 | $17.3M | 733,966 | 1.3% |
| Urogen Pharma Ltd(URGN) | Common | M96088105 | $17.0M | 943,803 | 1.3% |
| Bright Minds Biosciences Inc(DRUG) | Common | 10919W405 | $15.5M | 212,175 | 1.2% |
| Zymeworks, Inc.(ZYME) | Common | 98985Y108 | $14.2M | 565,249 | 1.1% |
| Belite Bio Inc(BLTE) | SPONSORED ADS | 07782B104 | $14.0M | 88,045 | 1.1% |
| Viridian Therapeutics Inc(VRDN) | Common | 92790C104 | $12.7M | 649,873 | 1.0% |
| enGene Holdings, Inc.(ENGN) | Common | 29286M105 | $12.6M | 1,845,373 | 1.0% |
| Abivax SA(ABVX) | SPONSORED ADS | 00370M103 | $11.9M | 107,268 | 0.9% |
| Allogene Therapeutics, Inc.(ALLO) | Common | 019770106 | $5.5M | 2,242,933 | 0.4% |
| Aclaris Therapeutics Inc(ACRS) | Common | 00461U105 | $1.5M | 391,918 | 0.1% |
| Werewolf Therapeutics, Inc.(HOWL) | Common | 95075A107 | $1.0M | 1,208,810 | 0.1% |